COVID-19 revisiting inflammatory pathways of arthritis.
Nat Rev Rheumatol
; 16(8): 465-470, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-606957
ABSTRACT
Coronavirus disease 2019 (COVID-19) is an infectious disease, caused by severe acute respiratory syndrome coronavirus 2, which predominantly affects the lungs and, under certain circumstances, leads to an excessive or uncontrolled immune activation and cytokine response in alveolar structures. The pattern of pro-inflammatory cytokines induced in COVID-19 has similarities to those targeted in the treatment of rheumatoid arthritis. Several clinical studies are underway that test the effects of inhibiting IL-6, IL-1ß or TNF or targeting cytokine signalling via Janus kinase inhibition in the treatment of COVID-19. Despite these similarities, COVID-19 and other zoonotic coronavirus-mediated diseases do not induce clinical arthritis, suggesting that a local inflammatory niche develops in alveolar structures and drives the disease process. COVID-19 constitutes a challenge for patients with inflammatory arthritis for several reasons, in particular, the safety of immune interventions during the pandemic. Preliminary data, however, do not suggest that patients with inflammatory arthritis are at increased risk of COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Arthritis, Rheumatoid
/
Pulmonary Alveoli
/
Coronavirus Infections
/
Cytokine Release Syndrome
Type of study:
Prognostic study
Topics:
Long Covid
Language:
English
Journal:
Nat Rev Rheumatol
Journal subject:
Rheumatology
Year:
2020
Document Type:
Article
Affiliation country:
S41584-020-0451-z
Similar
MEDLINE
...
LILACS
LIS